Huimei Capital

Sniper develops accurate and intelligent molecular diagnostic solutions. Taking the next-generation fully automatic digital PCR as a breakthrough, the company has developed a droplet generation method with global independent intellectual property rights - Vibrant Injection technology and created a new path of chip-free droplet generation technology. It solves the pain points of high cost and complicated operation of microfluidic technology in practical application and is expected to bring subversive innovation in the field of refined medical testing.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company's therapeutics are designed to significantly reduce the mortality and morbidity associated with these infections, as well as the related healthcare costs. Osteal Therapeutics offers solutions for orthopedic infections, including those affecting infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for musculoskeletal diseases, enhancing patient outcomes and addressing a critical need in the field of infection therapeutics.

Xushui Internet provides image equipment monitoring, operation, and maintenance cloud services, large-scale equipment IoT management system, digital integration services for hospital-wide equipment, and remote collaborative image inspection system.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company's therapeutics are designed to significantly reduce the mortality and morbidity associated with these infections, as well as the related healthcare costs. Osteal Therapeutics offers solutions for orthopedic infections, including those affecting infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for musculoskeletal diseases, enhancing patient outcomes and addressing a critical need in the field of infection therapeutics.

SensView is a company focused on the development and production of solid-state imaging chips and detector modules. Its primary offerings include CMOS flat panel detectors, X-ray detectors like CT detectors and photon counting detectors, as well as other imaging solutions based on monocrystalline silicon technology. These products serve a range of industrial applications, highlighting SensView's commitment to innovation in imaging technology.

Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating the effectiveness of protein design.

Bio-Engine specializes in the research and development of veterinary biological products, focusing on the creation and manufacturing of antibodies, recombinant proteins, and vaccines for both human and livestock viruses. The company utilizes high-density serum-free suspension culture technology for animal cells, which enhances the efficiency of its products. Key offerings include serum-free media for various cell types, such as HEK293 and PK15, applicable in fields like cell therapy and vaccine production. In addition to product development, Bio-Engine provides clinical trial services to pharmaceutical manufacturers and scientific research organizations. Founded in 2014 and headquartered in Shanghai, China, the company is committed to advancing biotechnological solutions in the veterinary sector.

Coherent Biopharma is a pharmaceutical company focused on the development of innovative drug therapies for oncology and chronic diseases. The company utilizes its proprietary bi-targeting drug conjugation technology, which includes platforms such as BEST™, C-PROTAC, and a specific Chronic Diseases Platform. This advanced approach enables the creation of drugs that target multiple chronic conditions through tissue and organ site-specific delivery. Coherent Biopharma aims to enhance treatment options for patients by promoting the development of targeted therapies that address complex health challenges.

Xinrui Medical is a domestic enterprise that engages in the research and development of polymer valves. It focuses on new polymer valves to build a complete solution for heart valve disease. The team members have long been engaged in the research and development of polymer synthesis and polymer-related medical devices. They are all from well-known medical device companies and have complete product development experience and mature industrialization thinking.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

Ruitai Biotechnology offers research, development, production, and sales of regenerative repair materials and related medical device products. They provide relevant technical services for other start-up biomedical companies to help them realize the transformation of scientific and technological achievements.

Lechun Biology is an enterprise engaged in disposable products and leak detection equipment in the biotechnology and pharmaceutical industries. The company develops and produces disposable biopharmaceutical process equipment and consumables. The products are used for the storage, transportation, filling and leak detection of various samples in biosimilars, vaccines and other biopharmaceutical processes. The core product is a disposable storage bag. Recently completed B+ round of financing. This round of financing will be mainly used for the development of a number of innovative new products, the establishment of a US R&D center, the integration of the upstream industrial chain, the securing of the supply chain, and the expansion of the R&D market operation team at home and abroad.

Sunpower Group is an enterprise driven by green investment, based and supported by manufacturing and engineering services, and driven by R&D and innovation. Sunpower Group is headquartered in Nanjing, Jiangning.

Jinjiang Electronic Technology is a med-tech company focused on the research and development as well as the manufacture of advanced medical equipment designed to enhance patient care in the field of cardiac electrophysiology. The company offers a range of innovative products, including a 3D cardiac mapping system, electrophysiology recording system, cardiac RF ablation generator, and irrigation pump. These devices provide comprehensive solutions aimed at diagnosing and treating arrhythmias, ultimately improving the quality of life for patients with heart conditions.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To address clients' therapeutic product demands at the pre-clinical, clinical, and commercial stages, the firm offers end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Coherent Biopharma is a pharmaceutical company focused on the development of innovative drug therapies for oncology and chronic diseases. The company utilizes its proprietary bi-targeting drug conjugation technology, which includes platforms such as BEST™, C-PROTAC, and a specific Chronic Diseases Platform. This advanced approach enables the creation of drugs that target multiple chronic conditions through tissue and organ site-specific delivery. Coherent Biopharma aims to enhance treatment options for patients by promoting the development of targeted therapies that address complex health challenges.

Ruitai Biotechnology offers research, development, production, and sales of regenerative repair materials and related medical device products. They provide relevant technical services for other start-up biomedical companies to help them realize the transformation of scientific and technological achievements.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

Gokin Solar specializes in the research and development, as well as the manufacturing, of high-efficiency, large-size photovoltaic silicon wafers. The company produces monocrystalline silicon rods and wafers, including sizes such as 182mm and 210mm, which are utilized in various applications, including large ground-based centralized power plants, industrial and commercial sectors, and residential photovoltaic systems. By delivering high-performance and superior-quality silicon wafers, Gokin Solar supports enterprises within the photovoltaic industry in enhancing their energy solutions.

SensView is a company focused on the development and production of solid-state imaging chips and detector modules. Its primary offerings include CMOS flat panel detectors, X-ray detectors like CT detectors and photon counting detectors, as well as other imaging solutions based on monocrystalline silicon technology. These products serve a range of industrial applications, highlighting SensView's commitment to innovation in imaging technology.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company's therapeutics are designed to significantly reduce the mortality and morbidity associated with these infections, as well as the related healthcare costs. Osteal Therapeutics offers solutions for orthopedic infections, including those affecting infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for musculoskeletal diseases, enhancing patient outcomes and addressing a critical need in the field of infection therapeutics.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Quanrong Pharmaceutical has a nationally leading expert team in software engineering, information security, and product design. The product developed by the company is currently the leading clinical trial management system in the country, with a large number of independent intellectual property rights and extensive support from the clinical trial community. Through strategic cooperation, the company will jointly develop products suitable for global clinical trial informatization with strategic partners in North America and Europe within a few years, and will become the world's leading clinical trial informatization company.

Deyun Kangrui is a bio-medical high-tech enterprise that integrates R&D and the production of full-chain single-cell multi-omics technology.

Yingmai Medical offers solutions for valve intervention, aortic and peripheral intervention, and neuromodulation. They are covering multiple innovative technology fields, such as structural heart disease treatment, pan-vascular disease treatment, nerve stimulation, and a brain-computer interface platform.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To meet the therapeutic product needs of our clients at the pre-clinical, clinical, and commercial stages, we offer end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing novel therapeutics for oncology and infectious diseases. The company focuses on targeting dysfunctional metabolic pathways, particularly through its expertise in fatty acid synthase (FASN) biology. Its lead drug candidate, denifanstat, is a selective FASN inhibitor designed for the treatment of nonalcoholic steatohepatitis (NASH) and is administered as an oral, once-daily pill. Additionally, Sagimet is working on antiviral therapeutics aimed at addressing respiratory syncytial virus, cytomegalovirus, and other human pathogens. Originally known as 3-V Biosciences, Inc., the company rebranded to Sagimet Biosciences in August 2019 and has been active since its incorporation in 2006.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer and autoimmune diseases. The company's portfolio features several key candidates, including CD24Fc, a recombinant fusion protein aimed at preventing acute graft versus host disease in leukemia patients undergoing hematopoietic stem cell transplantation. OncoImmune has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication. Additionally, the company is developing sialidase inhibitors to prevent sepsis, ONC-392, a monoclonal antibody that minimizes immune-related toxicities while maintaining anti-tumor activity, and Echinomycin, a formulation for treating acute myeloid leukemia. Founded in 2000, OncoImmune is headquartered in Rockville, Maryland.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

100doc is a Beijing-based live streaming video platform dedicated to enhancing medical knowledge and communication among healthcare professionals in China. The platform offers an interactive environment for online meetings, lectures, and training specifically for doctors. Additionally, it features a cloud-based software-as-a-service (SaaS) solution that enables medical institutions to record, store, manage, and share medical records, procedural operation recordings, and educational content. By facilitating the efficient exchange of information, 100doc aims to support the dissemination of leading medical knowledge and foster collaboration within the medical community across China.

Huimei Technology specializes in developing and designing artificial intelligence solutions aimed at enhancing clinical quality in healthcare. The company’s core offerings include a single disease process quality management system and a Clinical Decision Support System (CDSS) that integrates an evidence-based medical knowledge base. Utilizing advanced techniques such as natural language processing and deep learning, Huimei Technology processes clinical big data to provide real-time decision-making assistance for healthcare professionals. This integration of standard electronic clinical pathways and workflows allows clinicians to deliver more personalized and effective diagnoses and treatment plans based on individual patient conditions. The company's products are primarily targeted for use in outpatient, emergency, and inpatient settings within large hospitals, ultimately aiming to improve patient outcomes and the overall efficiency of medical services.